KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cell Communication and Signaling

Topics

Biology

Biochemistry

Chemistry

Medicine

Internal Medicine

Show all topics

DOI

10.1186/s12964-024-01667-x

License

CC-BY

Other Formats

PDF